Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | ENPP2 | Q13822 | 4/20 | 0.38 |
| ▸ | ATXN2 | Q99700 | 4/20 | 0.38 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.37 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.37 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 3/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9994844 | 0.88 | ENPP2 (0.42) | MEN1KMT2AENPP2ATXN2ROCK2 | |
| SCHEMBL8510015 | 0.83 | GABRA5 (0.39) | MEN1KMT2APKMRAB9ANPC1 | |
| SCHEMBL9993019 | 0.82 | SCD5 (0.45) | ENPP2ATXN2SCD5PKM | |
| SCHEMBL9994209 | 0.80 | NAMPT (0.44) | SCD5PKM | |
| SCHEMBL9994514 | 0.80 | NAMPT (0.44) | MEN1KMT2ASCD5PKM | |
| Trifluoroacetic Acid SCHEMBL9993827 | 0.78 | ROCK2 (0.39) | MEN1KMT2AENPP2ATXN2ROCK2 | |
| SCHEMBL346185 | 0.77 | PKM (0.42) | MEN1KMT2ASCD5MAPTPKM | |
| SCHEMBL25383393 | 0.76 | NR1H2 (0.42) | MEN1KMT2APKMRAB9ANPC1 | |
| SCHEMBL27081666 | 0.75 | ENPP2 (0.57) | MEN1KMT2AENPP2ATXN2ROCK2 | |
| Trifluoroacetic Acid SCHEMBL9994863 | 0.75 | ROCK2 (0.37) | MEN1KMT2AENPP2ATXN2ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8889702-B2 | Derivatives of azaspiranyl-alkylcarbamates of 5-member heterocyclic compounds, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2014-11-18 | — | — | US | disclosed |
| US-20110319381-A1 | DERIVATIVES OF AZASPIRANYL-ALKYLCARBAMATES OF 5-MEMBER HETEROCYCLIC COMPOUNDS, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2011-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319381-A1 | DERIVATIVES OF AZASPIRANYL-ALKYLCARBAMATES OF 5-MEMBER HETEROCYCLIC COMPOUNDS, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | PRMT9, IDH3B, DHFR | MEN1 262/4885KMT2A 1399/4885ENPP2 671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.